Compelling evidence from landmark clinical trials, particularly STEP-HFpEF, STEP-HFpEF DM and SUMMIT, has established the efficacy of GLP-1RAs in improving HF-related symptoms and quality of life, as well as reducing worsening HF events, in the prevalent phenotype of HFpEF in the setting of obesity and T2D
His average systolic blood pressure improved from ~170 to ~140 despite discontinuation of his antihypertensive regimen, and his chronic non-healing leg wound resolved without antibiotics
Characterization of recombinant human interleukin-2 with micromethods
Like Wegovy, common side effects of semaglutide and Ozempic include gastrointestinal symptoms like nausea, vomiting, diarrhea, and constipation
The researchers didn't dive into why GLP-1s may have this impactthey just found a link